Detailed View
PRLD - Prelude Therapeutics Incorporat
Latest filing: 2026-03-31 | Reporting: gaap
Market Cap
392,651,328
Adj EBIT (TTM)
-84,137,000
Enterprise Value
311,097,328
Last Price
4.93
Earnings Yield
-27.05%
Return on Capital
-107.98%
Capital
77,922,000
1Y Price Chart
Last Price: -
1Y Change: -
Company Summary
Loading summary...
| endDate | formType | fiscalYear | Revenue | OperatingIncomeLoss |
|---|---|---|---|---|
| 2026-03-31 | 10-Q | 2026 | 4,580,000 | -14,177,000 |
| 2025-12-31 | 10-K (Q4 derived) | 2025 | 5,640,000 | -17,348,000 |
| 2025-09-30 | 10-Q | 2025 | 6,500,000 | -20,418,000 |
| 2025-06-30 | 10-Q | 2025 | 0 | -32,194,000 |
| 2025-03-31 | 10-Q | 2025 | 0 | -34,606,000 |
| 2024-12-31 | 10-K (Q4 derived) | 2024 | 4,000,000 | -33,831,000 |
| 2024-09-30 | 10-Q | 2024 | 3,000,000 | -34,376,000 |
| 2024-06-30 | 10-Q | 2024 | 0 | -37,164,000 |
Notice something wrong?
Submit a quick report with a snapshot of the values you are seeing.